Edition:
United States

Danaher Corp (DHR.N)

DHR.N on New York Stock Exchange

80.00USD
11:48am EST
Change (% chg)

$-0.53 (-0.66%)
Prev Close
$80.53
Open
$80.32
Day's High
$80.46
Day's Low
$79.86
Volume
167,247
Avg. Vol
917,337
52-wk High
$102.78
52-wk Low
$75.71

Select another date:

Tue, Jan 17 2017

Two settle U.S. charges on failing to file stock buys with regulator

WASHINGTON Danaher Corp co-founder Mitchell Rales agreed to pay $720,000 to settle allegations that he failed to report stock purchases to the government so that they could be vetted to determine if they violate antitrust law, antitrust enforcers said on Tuesday.

Two settle U.S. charges on failing to file stock buys with regulator

WASHINGTON Danaher Corp co-founder Mitchell Rales agreed to pay $720,000 to settle allegations that he failed to report stock purchases to the government so that they could be vetted to determine if they violate antitrust law, antitrust enforcers said on Tuesday.

Two settle U.S. charges on failing to file stock buys with regulator

WASHINGTON, Jan 17 Danaher Corp co-founder Mitchell Rales agreed to pay $720,000 to settle allegations that he failed to report stock purchases to the government so that they could be vetted to determine if they violate antitrust law, antitrust enforcers said on Tuesday.

BRIEF-Danaher enters new $3 bln 364-day revolving credit facility

* Danaher Corp says on Oct. 24 entered into a new $3.0 billion 364-day revolving credit facility with Morgan Stanley Senior Funding, Inc

BRIEF-Cepheid receives required regulatory clearances in proposed acquisition by Danaher

* Cepheid announces receipt of required regulatory clearances in proposed acquisition by Danaher Corporation Source text for Eikon: Further company coverage:

BRIEF-Danaher reports Q3 earnings per share $0.57

* Q3 earnings per share view $0.82 -- Thomson Reuters I/B/E/S

BRIEF-S&P places Danaher Corp. 'A' ratings on watch negative on planned acqusition of Cepheid

* S&P - Danaher Corp. 'A' ratings placed on watch negative on planned acqusition of Cepheid

Danaher to buy Cepheid in $4 billion deal to expand in diagnostics

Danaher Corp said on Tuesday it would buy medical diagnostics company Cepheid in a deal valued at $4 billion, including debt, that will strengthen its presence in molecular diagnostics.

UPDATE 3-Danaher to buy Cepheid in $4 bln deal to expand in diagnostics

Sept 6 Danaher Corp said on Tuesday it would buy medical diagnostics company Cepheid in a deal valued at $4 billion, including debt, that will strengthen its presence in molecular diagnostics.

BRIEF-Moody's says Danaher's A2 rating unaffected by planned acquisition of Cepheid

* Moody's: Danaher's A2 rating unaffected by planned acquisition of Cepheid for $4 billion Source text for Eikon: Further company coverage:,

Select another date: